Active, not recruitingPhase 3NCT03941236
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Studying Hyperinsulinemic hypoglycaemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zealand Pharma
- Principal Investigator
- Clinical Trial Information DeskZealand Pharma
- Intervention
- dasiglucagon(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 13 years · All sexes
- Timeline
- 2019 – 2026
Study locations (10)
- Children's Hospital Colorado, Aurora, Colorado, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Cook Children's Endocrinology and Diabetes Clinic, Fort Worth, Texas, United States
- University Hospital Düsseldorf, Department of Pediatrics, Düsseldorf, Germany
- Otto von Guericke University Magdeburg, Department of Pediatrics, Magdeburg, Germany
- Hadassah Medical Center, Jerusalem, Israel
- NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
- Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, United Kingdom
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
- Manchester University NHS Foundation Trust, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03941236 on ClinicalTrials.govOther trials for Hyperinsulinemic hypoglycaemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06208215RZ358 Treatment for Congenital HyperinsulinismRezolute
- RECRUITINGPHASE2NCT04732416HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)Hanmi Pharmaceutical Company Limited
- RECRUITINGPHASE2NCT0420560418FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital HyperinsulinismMiguel Pampaloni
- RECRUITINGPHASE1NCT02021604Fluorodopa F 18 in Congenital Hyperinsulinism and InsulinomaCook Children's Health Care System